Zidometacin is a non-steroidal anti-inflammatory drug (NSAID) that was initially developed for the treatment of inflammatory conditions. It is a potent inhibitor of cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins, substances that contribute to inflammation and pain. However, zidometacin's clinical development was halted due to concerns about its potential for gastrointestinal side effects, including ulceration and bleeding. Despite its limited clinical use, zidometacin remains of interest to researchers due to its unique chemical structure and its ability to inhibit COX enzymes. Further research is needed to explore its potential therapeutic applications and to investigate its mechanisms of action and safety profile. '
| ID Source | ID |
|---|---|
| PubMed CID | 44179 |
| CHEMBL ID | 2107615 |
| MeSH ID | M0093402 |
| Synonym |
|---|
| zidometacin |
| indole-3-acetic acid, 1-(4-azidobenzoyl)-5-methoxy-2-methyl- |
| 1-(p-azidobenzoyl)-5-methoxy-2-methylindole-3-acetic acid |
| 1-(4-azidobenzoyl)-5-methoxy-2-methyl-indole-3-acetic acid |
| zidometacina [inn-spanish] |
| zidometacine [inn-french] |
| zidometacin [usan:inn] |
| 1h-indole-3-acetic acid, 1-(4-azidobenzoyl)-5-methoxy-2-methyl- |
| einecs 263-740-5 |
| zidometacinum [inn-latin] |
| 62851-43-8 |
| zidometacin (usan/inn) |
| D06364 |
| 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid |
| CHEMBL2107615 |
| zidometacinum |
| 446vqg66lc , |
| zidometacine |
| unii-446vqg66lc |
| zidometacina |
| zidometacin [usan] |
| zidometacin [mart.] |
| zidometacin [inn] |
| zidometacin [who-dd] |
| DTXSID40212024 |
| Q27258718 |
Zidometacin is a new nonsteroidal antiinflammatory agent structurally related to indomethacin.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Zidometacin is a new nonsteroidal antiinflammatory agent structurally related to indomethacin. " | ( Zidometacin: pharmacokinetic study on oral absorption. Bonardi, G; Colombo, F; Guenzati, G; Lepore, AM; Sega, R, 1984) | 3.15 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters and bioavailability of the drug were evaluated in the present study after the administration of a single oral dose." | ( Zidometacin: pharmacokinetic study on oral absorption. Bonardi, G; Colombo, F; Guenzati, G; Lepore, AM; Sega, R, 1984) | 1.71 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters and bioavailability of the drug were evaluated in the present study after the administration of a single oral dose." | ( Zidometacin: pharmacokinetic study on oral absorption. Bonardi, G; Colombo, F; Guenzati, G; Lepore, AM; Sega, R, 1984) | 1.71 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||